VINCRISTINE SULFATE INJECTION 1 MG
VINCRISTINE SULFATE : 1 MG · DIN 02143305 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is VINCRISTINE SULFATE INJECTION?
VINCRISTINE SULFATE INJECTION 1 MG contains VINCRISTINE SULFATE : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02143305, held by TEVA CANADA LIMITED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 12-Apr-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VINCRISTINE SULFATE INJECTION used for?
Acute leukemia, Hodgkin's disease, lymphomas, various sarcomas, breast cancer, lung cancer, Wilms' tumor, and refractory idiopathic thrombocytopenic purpura.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02143305 |
|---|---|
| Brand name | VINCRISTINE SULFATE INJECTION |
| Generic / active ingredient | VINCRISTINE SULFATE : 1 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 1 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01CA02 VINCRISTINE |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Apr-2014 |
| Original market date | 1997-01-21 00:00:00 |
How is it administered?
Intravenous use only at weekly intervals. Usual dose: 2 mg/m2 for children, 1.4 mg/m2 for adults. For children ≤10 kg, start at 0.05 mg/kg. Dilute in flexible plastic container.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store under refrigeration (2° to 8°C). Do not freeze. Protect from light.
How is it supplied?
Pharmacy Bulk Vials containing 1 mg/mL in 5 mL sterile, unpreserved solution.
Contraindications
Patients with the demyelinating form of Charcot-Marie-Tooth Syndrome.
Warnings and precautions
FOR INTRAVENOUS USE ONLY; FATAL IF GIVEN BY OTHER ROUTES. Intrathecal administration usually results in death. Avoid extravasation (tissue irritation). Monitor blood counts weekly.
Is VINCRISTINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by TEVA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01CA02 VINCRISTINE. 2 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| VINCRISTINE SULFATE INJECTION USP | 1 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02183013 |
| ONCOVIN SOLUTION 1MG/ML | 1 MG | LIQUID | ELI LILLY CANADA INC | CANCELLED POST MARKET | DIN 00611182 |
| VINCRISTINE SULFATE INJ 1MG/ML USP | 1 MG | LIQUID | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | DIN 00726575 |
| VINCRISTINE SULFATE INJ 5MG/VIAL USP | 5 MG | POWDER FOR SOLUTION | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | DIN 00690317 |
| VINCRISTINE SULFATE INJECTION | 1 MG | SOLUTION | ACCORD HEALTHCARE INC | CANCELLED PRE MARKET | DIN 02324148 |
| VINCRISTINE SULFATE INJECTION USP | 1 MG | SOLUTION | UMAN PHARMA INC | CANCELLED PRE MARKET | DIN 02333198 |
Who else supplies VINCRISTINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. VINCRISTINE appears in 1989 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.